Skye Bioscience, Inc. (SKYE)
- Previous Close
2.0100 - Open
2.0100 - Bid 1.8400 x 100
- Ask 2.3000 x 200
- Day's Range
1.7800 - 2.0300 - 52 Week Range
1.1400 - 12.7700 - Volume
218,479 - Avg. Volume
695,095 - Market Cap (intraday)
57.941M - Beta (5Y Monthly) 1.75
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8300 - Earnings Date Aug 7, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.64
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
skyebioscience.comRecent News: SKYE
View MorePerformance Overview: SKYE
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SKYE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SKYE
View MoreValuation Measures
Market Cap
57.94M
Enterprise Value
-871.09k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.98
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.04%
Return on Equity (ttm)
-47.27%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-32.65M
Diluted EPS (ttm)
-0.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
59.22M
Total Debt/Equity (mrq)
0.70%
Levered Free Cash Flow (ttm)
-14.01M